The FDA on September 25, 2025, approved INLURIYO® , an estrogen receptor antagonist, for adults with estrogen receptor (ER)-positive, human epidermal growth factor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. INLURIYO® is a product of Eli Lilly and Company.
Bottom Ad
Advertisement
Subscribe
